These guidelines on the use of PrEP were open for public consultation from Thursday 24th August until 1730 on Friday 29th September 2017.
The guidelines aim to provide evidence-based guidance on best clinical practice in the provision, monitoring and support of pre-exposure prophylaxis (PrEP) for the prevention of HIV acquisition. The guidelines include:
(i) guidance on risk assessment prior to PrEP;
(ii) baseline assessment;
(iii) dosing schedules;
(v) supporting adherence;
(vi) buying generic PrEP; and
(vii) cost effectiveness.
The guidelines are aimed at clinical professionals directly involved in, and responsible for, HIV prevention, and at community advocates and organisations responsible for supporting HIV prevention strategies in those at risk of HIV acquisition.
The consultation period has now closed.